A Dutch clinical trial published in JAMA Cardiology found that daily supplementation with menaquinone-7 (MK-7), a form of vitamin K2, measurably slowed the buildup of calcium deposits in coronary arteries over two years. Participants with existing coronary artery disease who took MK-7 showed significantly lower CAC scores and calcium mass compared to placebo. The benefit appeared most pronounced in early-to-moderate noncalcified plaques. Researchers caution the effect is modest and clinical outcomes like heart attacks or mortality were not measured. Still, the findings add meaningful evidence that vitamin K2 may play a protective role in cardiovascular health, particularly for those already showing signs of atherosclerosis.
